This website uses cookies in order to improve our services. If you proceed visiting this website you accept the usage of cookies. For more info please read our Data Privacy statement.

 

Roche launches AVENIO ctDNA Analysis Kits for Oncology Research

Basel, 08 May 2017 
Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced the global commercial launch of the AVENIO circulating tumor DNA (ctDNA) Analysis Kits, a portfolio of three next-generation sequencing (NGS) liquid biopsy assay kits for oncology research: the AVENIO ctDNA Targeted Kit, Expanded Kit and Surveillance Kit. The kits include all reagents, bioinformatics and software to make ctDNA testing accessible to all NGS laboratories.

“We are pleased to introduce these state-of-the-art AVENIO ctDNA Analysis Kits1,2,3 that combine the convenience of liquid biopsy with the power of next generation sequencing,” said Roland Diggelmann, Chief Executive Officer, Roche Diagnostics. “Roche believes the AVENIO ctDNA assays can help researchers around the world advance personalized oncology by enabling them to carry out their own testing.”

The AVENIO ctDNA Analysis Kits are aligned with NCCN guidelines to support oncology research4. The kits detect all four mutation classes with high sensitivity3. With three different kits available, researchers can profile the genomic complexities of different cancer stages and tumor types, obtaining results in five days.
“As a cancer researcher, I see a tremendous advantage to using the AVENIO ctDNA Analysis Kits”, said Peter Meldgaard, MD, PhD, Associate Professor of Oncology at Aarhus University in Denmark. “Cancer is a highly complex disease, so the ability to obtain a complete and accurate genomic profile of malignant tumors and monitor changes in tumor burden is invaluable.”

Source: Roche, Basel


 

Pin It